在埃及资源有限的环境中实施具有成本效益的基于证据的儿童癌症治疗的障碍和促进者:质量访谈研究
Ranin Soliman1,2, Carl Heneghan3, Anne-Marie Boylan3
1Department of Continuing Education, University of Oxford, Oxford, United Kingdom.
JCO global oncology
|June 8, 2023
概括
在埃及实施具有成本效益的儿童癌症治疗,面临着数据和资源有限等障碍. 促进者包括领导力支持和当地数据的可用性,这对于改善儿科瘤护理至关重要.
科学领域:
- 儿科瘤学 儿科瘤学
- 卫生经济学 卫生经济学
- 基于证据的医学基于证据的医学.
背景情况:
- 儿童癌症的治疗是复杂的,资源密集的,特别是在资源较低的环境中.
- 实施具有成本效益的,基于证据的治疗方法需要了解影响因素.
- 埃及是一个资源有限的环境,需要为儿童癌症护理提供具有成本效益的方法.
研究的目的:
- 确定临床医生对实施成本效益高,基于证据的儿童癌症治疗在埃及的障碍和促进者的看法.
- 在资源有限的环境中,为改善儿科瘤护理的策略提供信息.
主要方法:
- 使用与高级儿科瘤学临床医生进行半结构面试的定性研究.
- 有目的的抽样招募14名参与者 (儿科瘤学家,外科医生,放射瘤学家).
- 对面试数据进行主题分析,以识别障碍和促进者.
主要成果:
- 主要障碍包括缺乏成本效益数据,资源有限以及证据与实践的差距.
- 促进者包括采用标准协议,领导支持,本地数据可用性和现有的研究技能.
- 参与者提出了建议,以加强成本有效的治疗方案的实施.
结论:
- 该研究提供了关于埃及儿童癌症治疗成本效益的障碍和促进因素的见解.
- 提供了实用建议,以解决落实差距.
- 这些发现对临床实践,卫生政策和儿科瘤学的未来研究有影响.
相关概念视频
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
ABC Transporters: Exporter
4.4K
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
4.4K
Hazard Ratio
168
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
168


